(function(){var loadHandler=window['sl_{59CE9567-A535-4D8F-A650-48179E9E27C7}'];loadHandler&&loadHandler(11, '<div id="spr0_db0cb3b"><div id="spr1_db0cb3b" class="kern slide"><img id="img0_db0cb3b" src="data/img1.jpg" width="960px" height="720px" alt="" style="left:0px;top:0px;"/></div><div id="spr2_db0cb3b" class="kern slide"><div id="spr3_db0cb3b" style="left:16px;top:36.667px;"><div style="width:0px;"><span id="txt0_db0cb3b" class="nokern" data-width="630.541687" style="left:148.75px;top:-1.801px;">MOST PROMINENT FEATURES</span></div><div style="width:0px;"><span id="txt1_db0cb3b" class="nokern" data-width="654.291687" style="left:136.837px;top:49.399px;">OF PHARMACEUTICAL PRICING</span></div><div style="width:0px;"><span id="txt2_db0cb3b" class="nokern" data-width="794.166687" style="left:66.917px;top:100.599px;">AND REIMBURSEMENT IN POLAND (2.)</span></div></div><div id="spr4_db0cb3b" style="left:24px;top:216px;"><div style="width:0px;"><span id="txt3_db0cb3b" class="nokern relpos" dir="auto" style="left:9.6px;top:6.424px;">•</span> <span id="txt4_db0cb3b" class="nokern relpos" data-width="732.750000" style="left:34.397px;top:6.424px;">Rule of compulsory 25% down - for price of any first</span></div><div style="width:0px;"><span id="txt5_db0cb3b" class="nokern" data-width="834.156250" style="left:45.6px;top:44.824px;">equivalent (in reference price group) in reimbursement lists</span></div></div><div id="spr5_db0cb3b" style="left:24px;top:216px;"><div style="width:0px;"><span id="txt6_db0cb3b" class="nokern relpos" dir="auto" style="left:9.6px;top:90.54px;">•</span> <span id="txt7_db0cb3b" class="nokern relpos" data-width="791.546875" style="left:34.397px;top:90.54px;">All further appearing competitors/equivalents – price not</span></div><div style="width:0px;"><span id="txt8_db0cb3b" class="nokern" data-width="820.046875" style="left:45.6px;top:129.304px;">higher than reference price within a given reference group</span></div></div><div id="spr6_db0cb3b" style="left:24px;top:216px;"><div style="width:0px;"><span id="txt9_db0cb3b" class="nokern relpos" dir="auto" style="left:9.6px;top:175.02px;">•</span> <span id="txt10_db0cb3b" class="nokern relpos" data-width="779.140625" style="left:34.397px;top:175.02px;">Lists of reimbursed products updated and published bi-</span></div><div style="width:0px;"><span id="txt11_db0cb3b" class="nokern" data-width="112.046875" style="left:45.6px;top:213.784px;">monthly</span></div></div><div id="spr7_db0cb3b" style="left:24px;top:216px;"><div style="width:0px;"><span id="txt12_db0cb3b" class="nokern relpos" dir="auto" style="left:9.6px;top:259.5px;">•</span> <span id="txt13_db0cb3b" class="nokern relpos" data-width="803.937500" style="left:34.397px;top:259.5px;">Risk-sharing schemes – yet another reason to do HTA in</span></div><div style="width:0px;"><span id="txt14_db0cb3b" class="nokern" data-width="261.468750" style="left:45.6px;top:298.264px;">different scenarios</span></div></div><div id="spr8_db0cb3b" style="left:24px;top:216px;"><div style="width:0px;"><span id="txt15_db0cb3b" class="nokern relpos" dir="auto" style="left:9.6px;top:343.98px;">•</span> <span id="txt16_db0cb3b" class="nokern relpos" data-width="732.718750" style="left:34.397px;top:343.98px;">Full compliance with the EU Transparency Directive</span></div></div><div id="spr9_db0cb3b" style="left:24px;top:216px;"><div style="width:0px;"><span id="txt17_db0cb3b" class="nokern relpos" dir="auto" style="left:9.6px;top:390.06px;">•</span> <span id="txt18_db0cb3b" class="nokern relpos" data-width="850.171875" style="left:34.397px;top:390.06px;">Great role of HTA and state HTA agency in decision-making</span></div><div style="width:0px;"><span id="txt19_db0cb3b" class="nokern" data-width="569.156250" style="left:45.6px;top:428.824px;">processes of pricing and reimbursement</span></div></div><div id="spr10_db0cb3b" style="left:688px;top:655.667px;"><div style="width:0px;"><span id="txt20_db0cb3b" data-width="20.763020" style="left:193.6px;top:5.747px;">12</span></div></div></div></div>', '{"s":[]}');})();